SCHEMBL16185145

SCHEMBL16185145

CCOc1cc(-c2cccc(F)c2F)cc2c(NC)nc(-c3cnccn3)nc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 6/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ FGFR2 P21802 1/20 0.35
▸ KLKB1 P03952 1/20 0.34
▸ LIMK1 P53667 1/20 0.34
▸ MAPK14 Q16539 1/20 0.34
▸ CHRNA7 P36544 2/20 0.33
▸ GSK3B P49841 2/20 0.33
▸ GSK3A P49840 1/20 0.33
▸ PIM1 P11309 3/20 0.33
▸ PIM3 Q86V86 1/20 0.33
▸ PIM2 Q9P1W9 1/20 0.33
▸ S1PR1 P21453 1/20 0.32
▸ S1PR3 Q99500 1/20 0.32
▸ PIP4K2A P48426 1/20 0.32
▸ PLK4 O00444 1/20 0.32
▸ MAPK13 O15264 1/20 0.32
▸ DAPK3 O43293 1/20 0.32
▸ PRKD3 O94806 1/20 0.32
▸ MAP4K4 O95819 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14475264 0.93 PIM1 (0.36) GRM5LIMK1MAPK14CHRNA7PIM1
SCHEMBL14474673 0.91 LMNA (0.38) PIM1PIM2DYRK1A
SCHEMBL14474689 0.89 FFAR1 (0.43) GRM5MAPK14S1PR1FFAR1
SCHEMBL16184366 0.89 ALOX5AP (0.38) GSK3BGSK3APIM1PIM3PIM2
SCHEMBL16184844 0.88 HSD17B10 (0.43) GRM5S1PR1CLK4
SCHEMBL14474686 0.88 SCN9A (0.37) GRM5FGFR1FGFR2KLKB1CHRNA7
SCHEMBL16185146 0.87 GRM5 (0.42) GRM5FGFR1FGFR2KLKB1CHRNA7
SCHEMBL14474679 0.87 KLKB1 (0.37) GRM5FGFR1FGFR2KLKB1CHRNA7
SCHEMBL16185157 0.86 CHRNA7 (0.39) GRM5LIMK1MAPK14CHRNA7
SCHEMBL14474684 0.86 CHRNA7 (0.39) GRM5KLKB1LIMK1MAPK14CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB GRM5 37/4885FGFR1 1609/4885FGFR2 2792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback